SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is dominating market conversation ahead of its anticipated Q4 delivery report, with community sentiment sharply divided. Bulls are optimistic, citing progress in robotics and emerging opportunities in autonomous services and energy storage, while bears express skepticism over sales growth, market competition, and the ambitious timelines for new ventures. This split underscores the ongoing debate about Tesla's core valuation, weighing its automotive performance against its long-term potential in AI and diversified tech.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is generating buzz as the community enters a new year, with many "apes" holding firm belief in a future rebound or "squeeze" fueled by the company's substantial cash reserves and CEO Ryan Cohen's long-term strategy. Despite a challenging recent performance, retail investors are actively debating potential catalysts like warrants and the awaited return of "Roaring Kitty" amidst persistent short interest and claims of market manipulation.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following the announcement of record December and Q4 vehicle deliveries, putting the company on the cusp of one million cumulative vehicles and sparking significant community discussion about its trajectory. Enthusiasts highlight strong growth, the competitive advantage of its battery swap network, and perceived undervaluation, while skeptics point to ongoing market volatility and potential manipulation. The core debate revolves around whether these improving fundamentals will translate into sustained stock performance and profitability in a highly competitive EV landscape.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates the end of year-end tax loss selling, fueling hopes for a new bull cycle and significant price rallies. While many enthusiasts are forecasting a moonshot for the meme coin in the new year, skeptics remain vocal about potential dips and question its long-term viability. The conversation reflects a strong divide, with active debate over whether current momentum signifies a true resurgence or merely a temporary bounce.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is a top trending stock, driven by strong community speculation around its extremely low share float and an active short squeeze narrative. The ongoing strategic review for a potential merger or sale is amplifying investor excitement, with many anticipating significant upward momentum and drawing comparisons to recent parabolic runners.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is a major topic of conversation as investors anticipate a potential housing market rebound fueled by lower interest rates and a broader 'January effect' for small-cap tech stocks. Bulls are enthusiastically discussing the company's operational shift to AI-powered real estate, believing new leadership has positioned it for a significant repricing. Conversely, skeptics highlight persistent selling pressure and question the path to long-term profitability, leading to a sharply divided outlook on its immediate trajectory.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is a major topic of conversation following news of a new strategic manufacturing partnership and a private placement. The community is sharply divided, with some highlighting the capital infusion and production scaling as strong growth catalysts for this low-float stock. Conversely, others warn of significant dilution from the offering and a potential "rug pull," fueling intense speculative trading and comparisons to other recent volatile runners.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is capturing significant attention due to major developments concerning its AI chip unit, Kunlunxin, which is reportedly pursuing a Hong Kong IPO and has garnered adoption from prominent AI developers. This, coupled with expanding global partnerships for its autonomous driving technology, fuels strong community conviction that Baidu is substantially undervalued and strategically positioned to lead China's domestic AI landscape.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

ALCY is generating significant community interest, trending as a low-float SPAC with traders actively comparing its potential to other recent "shell company" movers that have experienced substantial price surges. Bullish sentiment dominates discussions, with many investors looking to "load up" on dips amid expectations for a strong upward movement driven by its limited share float.

Trailblazer Merger Corp. I is a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or other similar business combination. The company was founded on November 12, 2021 and is headquartered in New York, NY.

Trailblazer Merger Corp I - Ordinary Shares - Class A

Trailblazer Merger Corp I ($TBMC) is drawing significant attention from the community, which sees it as a prime 'nano-float shell company' play poised for a substantial price surge. Speculation is high due to its exceptionally low share float, with many anticipating a trajectory similar to other recent low-float SPACs that have experienced rapid movements. The ongoing discussion around its proposed merger with the AI firm Cyabra further amplifies speculative interest, driving heightened conversation and trading volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BAYRY's 2025 Revival: Will the Momentum Continue in 2026? 

BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.

Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case

Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.

Why Bayer Aktiengesellschaft (BAYRY) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?

Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.

Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)

Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi 

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.

BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study 

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.

<ul class="summary-bullets"><li>Bayer said its new Phase III stroke study of asundexian hit both primary efficacy and safety goals.</li><li>The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.</li><li>The study enrolled more than 12,300 patients worldwide, and Bayer plans to engage with regulators as it prepares marketing submissions.</li></ul><p>Retail traders turned hyper bullish on Sunday after Bayer AG confirmed that its Phase III stroke study of asundexian met its primary efficacy and safety endpoints, two years after the company halted its separate OCEANIC-AF trial in 2023.&nbsp;</p><h2 class="st-heading-2"><strong>Asundexian Reduces Ischemic Stroke Risk&nbsp;</strong></h2><p>Bayer said patients taking 50 mg of asundexian once a day alongside antiplatelet therapy saw a meaningful drop in ischemic stroke risk compared with those given a placebo and antiplatelet therapy. The company added that the treatment did not lead to higher rates of major bleeding. Bayer said this is the first late-stage study of a drug in the Factor Xla inhibitor class, which helps prevent clots from forming, to be successfully completed.</p><h2 class="st-heading-2"><strong>Large Global Phase III Study&nbsp;</strong></h2><p>Bayer said the trial was&nbsp;conducted across multiple countries and medical centers, using a randomized, placebo-controlled design. More than 12,300 patients took part, all of whom had recently experienced a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The study tested whether adding asundexian to standard antiplatelet therapy could lower their chances of having another stroke.</p><h2 class="st-heading-2"><strong>High Burden Of Recurrent Strokes</strong></h2><p>The company noted the growing global need for better secondary stroke prevention. They said nearly 12 million people worldwide experience a stroke each year, and that 20%–30% are recurrent. One in five stroke survivors will have another stroke within five years, and recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk.</p><p>Mike Sharma, MD, principal investigator of OCEANIC-STROKE, said the topline results indicate that asundexian may become a new treatment option for reducing recurrent stroke risk.&nbsp;</p><h2 class="st-heading-2"><strong>Regulatory Path&nbsp;</strong></h2><p>Bayer said it will now engage with health authorities globally as it prepares to submit marketing authorization applications. Asundexian has Fast Track Designation from the U.S. Food and Drug Administration for stroke prevention in patients after a non-cardioembolic ischemic stroke. Bayer said asundexian remains investigational and is not approved in any country.</p><h2 class="st-heading-2"><strong>Halt Of OCEANIC-AF After Inferiority To Eliquis</strong></h2><p>Asundexian drew attention in 2023 when Bayer halted its OCEANIC-AF Phase III trial. Interim findings showed the drug did not perform as well as Eliquis, made by Bristol-Myers Squibb and Pfizer, in preventing strokes in high-risk atrial fibrillation patients. Bayer said the safety profile matched earlier studies and noted that independent trial supervisors advised continuing the stroke-focused OCEANIC-STROKE study.</p><p>Bayer said asundexian is part of the factor XI inhibitor drug class, which has also drawn interest from Novartis working with Blackstone, and from Bristol-Myers Squibb working with Johnson &amp; Johnson. The compound had been positioned as one of four new drug hopefuls Bayer said carried a combined peak sales potential of more than 12 billion euros. The program followed the company’s Xarelto blood thinner franchise, which is expected to lose protection from key European patents in 2026.</p><h2 class="st-heading-2"><strong>Stocktwits Mood Turns ‘Extremely Bullish’</strong></h2><p>On Stocktwits, retail sentiment for Bayer was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img style="aspect-ratio:970/142;" src="https://news.stocktwits-cdn.com/bayer_ss_png_e2cb5716df.webp" alt="bayer ss.png" width="970" height="142"><figcaption>BAYRY sentiment and message volume as of November 23 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/BAYRY">Bayer’s U.S.-listed stock</a> has risen 63% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Signage and the building of the Bayer AG pharmaceutical and biotechnology company are seen at one of its industrial sites in Wuppertal, North Rhine-Westphalia, Germany. (Photo by Michael Nguyen/NurPhoto via Getty Images)

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt

The update comes two years after the company halted the OCEANIC-AF trial when interim data showed asundexian was inferior to Eliquis.

Equity

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

BAYRY
Bayer AG (ADR)

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BAYRY News

BAYRYBayer AG (ADR)